Peptides for ADHD: Semax, Selank & Cognitive Research

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent inattention, impulsivity, and (in some presentations) hyperactivity, with onset in childhood and frequent persistence into adulthood. In the UK, it is estimated to affect 3–4% of adults — many of whom are undiagnosed or on long NHS waiting lists for assessment.

The neurobiological basis of ADHD involves dysregulation of dopaminergic and noradrenergic systems, particularly in the prefrontal cortex — the brain region responsible for executive function, working memory, impulse control and sustained attention. First-line pharmacological treatments (methylphenidate, lisdexamfetamine, atomoxetine) work by enhancing dopamine and/or noradrenaline signalling in these circuits.

Where research peptides enter the picture: Several peptides have been studied for their effects on brain-derived neurotrophic factor (BDNF), neuroplasticity, and dopaminergic/noradrenergic tone — mechanisms that overlap with ADHD pathophysiology. The two most researched in this context are Semax and Selank, both developed in Russia and studied primarily in Eastern European research settings.

It is critical to state from the outset: no peptide has been approved anywhere as a treatment for ADHD, and none should be considered a substitute for evidence-based ADHD assessment and treatment. The interest in these compounds is exploratory and research-based.

Semax is a synthetic analogue of the ACTH(4–10) fragment — a portion of adrenocorticotrophic hormone. It was developed at the Russian Institute of Molecular Genetics in the 1980s and has been used clinically in Russia for stroke rehabilitation, cognitive decline, and as a nootropic, though it is not licensed by the MHRA or EMA for any indication.

Proposed mechanisms relevant to ADHD: - BDNF upregulation: Semax has been shown in animal and limited human studies to increase BDNF expression in the hippocampus and prefrontal cortex — BDNF is critical for synaptic plasticity and learning - Dopaminergic modulation: Preclinical studies suggest Semax influences dopamine turnover in fronto-striatal circuits — the same circuits implicated in ADHD - Nootropic and attention effects: Studies in healthy volunteers and patients with ischaemic stroke have reported improvements in attention, working memory, and information processing speed - Neuroprotection: Semax has demonstrated neuroprotective effects in rodent models of neuronal damage through anti-inflammatory and antioxidant mechanisms

Limitations of the evidence: - Most Semax studies are Russian-language, small-scale, and not conducted to current Western regulatory trial standards - No randomised controlled trials in ADHD populations have been conducted; extrapolation from nootropic or stroke research is indirect - Semax is typically administered intranasally (as nasal drops) — an unusual route that affects bioavailability and reproducibility

Selank is a synthetic heptapeptide analogue of tuftsin, an endogenous immunomodulatory peptide. Like Semax, it was developed in Russia and has been investigated primarily for anxiety and cognitive performance. It is used in Russia as a licensed anxiolytic, but has no MHRA or EMA licence and is classified as a research compound in the UK.

Proposed mechanisms: - Anxiolytic activity via GABA-A modulation: Selank has been shown to modulate GABA-A receptor function in ways that reduce anxiety without the sedation or dependence associated with benzodiazepines — potentially relevant for the anxiety component of ADHD - BDNF enhancement: Similar to Semax, Selank appears to increase BDNF levels, supporting learning and memory consolidation - Serotonergic effects: Selank has been proposed to influence serotonin metabolism, which may contribute to mood stabilisation and reduced impulsivity - Cognitive protection under stress: Studies suggest Selank may preserve cognitive performance under conditions of high stress — potentially relevant given that ADHD-related cognitive difficulties are often exacerbated by anxiety

ADHD relevance: ADHD has high comorbidity with anxiety disorders — rates of 25–50% are reported in clinical samples. The anxiolytic profile of Selank is particularly interesting in this context, as traditional ADHD stimulant medications can worsen anxiety in some patients. The theoretical appeal is a compound that might address both anxiety and cognitive aspects simultaneously — but this remains entirely unproven in clinical trials.

Understanding the legal and access landscape for Semax and Selank in the UK is essential before considering any further research into these compounds.

Current UK legal status: - Neither Semax nor Selank is a controlled substance under the Misuse of Drugs Act 1971 - They are not licensed medicines in the UK and therefore cannot be legally marketed for human use, prescribed by UK doctors, or dispensed by UK pharmacies - Under the Human Medicines Regulations 2012, supplying an unlicensed medicine for human use is prohibited without a specific exemption - Importation for personal research use exists in a grey area — the MHRA has not issued specific guidance on personal importation of research peptides, and enforcement has historically focused on commercial supply rather than personal use

In practice: - Semax and Selank are available from research peptide suppliers who sell them explicitly for laboratory research use only — not for human consumption - The quality, purity and concentration of research-grade peptides vary between suppliers; the absence of pharmaceutical-grade manufacturing standards means contamination and dosing inaccuracies are real concerns - There is no regulated pathway through which a UK user can access medically supervised Semax or Selank administration

NHS and private routes: - No UK NHS service prescribes these peptides for ADHD - Private psychiatrists and GPs do not prescribe them as they are unlicensed - Patients seeking help for ADHD should pursue NHS assessment (via GP referral) or private ADHD psychiatry, where evidence-based treatments are available

This article would be incomplete without a clear statement of the evidence hierarchy and the risks of pursuing peptide alternatives over established ADHD treatment.

What the evidence actually supports for ADHD: - Stimulant medications (methylphenidate: Ritalin, Concerta; lisdexamfetamine: Vyvanse) have the most robust evidence base, with large-scale RCT data and decades of clinical use demonstrating efficacy for attention, impulsivity and hyperactivity - Non-stimulant medications (atomoxetine, guanfacine) have good evidence for adults who cannot tolerate stimulants or have specific contraindications - CBT and ADHD coaching have evidence for improving organisational skills and coping strategies - None of the research peptides discussed here have clinical trial evidence approaching this standard for ADHD

Risks of self-treating with research peptides instead of seeking diagnosis: - Delayed formal assessment and treatment — which has significant functional consequences for work, relationships, and mental health - Unknown purity and safety of research-grade compounds - No monitoring of cardiovascular, renal or other parameters that would normally accompany prescription medication

A reasonable framework: If you are interested in the potential cognitive-support properties of peptides like Semax or Selank as an adjunct to established ADHD treatment — not a replacement — that is a discussion to have with your prescribing psychiatrist or GP. They cannot prescribe these compounds, but they can contextualise the risk-benefit profile.

Pursue formal ADHD assessment through your GP (NHS) or a private ADHD assessment service — the waiting list pressure in the NHS makes private assessment worth considering if the cost is manageable.

*This article is for educational and research purposes only. It does not constitute medical advice and should not be used to self-diagnose or self-treat ADHD or any other condition.*